Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by Green Alpha Advisors LLC

Green Alpha Advisors LLC lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 5.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 61,845 shares of the company’s stock after acquiring an additional 3,174 shares during the quarter. Green Alpha Advisors LLC owned 0.09% of Editas Medicine worth $509,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in EDIT. Bank of New York Mellon Corp lifted its holdings in shares of Editas Medicine by 0.4% in the 1st quarter. Bank of New York Mellon Corp now owns 288,878 shares of the company’s stock worth $5,494,000 after acquiring an additional 1,060 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Editas Medicine by 13.6% in the 1st quarter. US Bancorp DE now owns 12,699 shares of the company’s stock worth $243,000 after acquiring an additional 1,520 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Editas Medicine by 88.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 41,811 shares of the company’s stock worth $795,000 after acquiring an additional 19,594 shares during the last quarter. Bank of Montreal Can acquired a new stake in Editas Medicine during the 1st quarter worth approximately $1,011,000. Finally, MetLife Investment Management LLC lifted its holdings in Editas Medicine by 57.4% during the 1st quarter. MetLife Investment Management LLC now owns 37,148 shares of the company’s stock worth $707,000 after buying an additional 13,546 shares in the last quarter. 76.61% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Editas Medicine news, SVP Baisong Mei sold 4,317 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $8.80, for a total transaction of $37,989.60. Following the transaction, the senior vice president now directly owns 72,055 shares of the company’s stock, valued at approximately $634,084. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 5,263 shares of company stock valued at $46,111. Insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EDIT. Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 target price on shares of Editas Medicine in a report on Wednesday. Raymond James upgraded shares of Editas Medicine from a “market perform” rating to an “outperform” rating and set a $17.00 target price on the stock in a report on Monday, June 12th. StockNews.com began coverage on shares of Editas Medicine in a report on Thursday, August 17th. They set a “sell” rating on the stock. Oppenheimer reiterated a “market perform” rating and set a $12.00 target price on shares of Editas Medicine in a report on Thursday, August 3rd. Finally, Chardan Capital reduced their target price on shares of Editas Medicine from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $15.57.

Editas Medicine Stock Down 0.8 %

NASDAQ EDIT opened at $8.40 on Friday. The firm’s fifty day moving average price is $8.81 and its 200 day moving average price is $8.62. Editas Medicine, Inc. has a 12 month low of $6.33 and a 12 month high of $16.16.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.20. Editas Medicine had a negative net margin of 1,065.39% and a negative return on equity of 55.14%. The company had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. During the same period last year, the firm posted ($0.78) EPS. Editas Medicine’s revenue for the quarter was down 54.6% on a year-over-year basis. Equities analysts anticipate that Editas Medicine, Inc. will post -2.55 EPS for the current year.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.